BPC158+TB500
XENE BIOLABS RESEARCH SERIES
FOR RESEARCH USE ONLY
Category: Healing Peptides | Half-life: BPC ~4h, TB-500 7-14 days
Mechanism
BPC-157 = gastric peptide, upregulates growth factors, angiogenesis, gut healing. TB-500 = Thymosin Beta-4 fragment, actin regulation, cell migration.
Dosing Protocol
Reconstitution: 5 mg each + 2.5 mL BAC = 2 mg/mL. 250 mcg = 0.125 mL = 12.5 units.
Critical: BPC site injection for local effect. TB-500 systemic. Can mix in same syringe.
BPC158+TB500 |
Tissue Repair & Recovery Blend | CAS: 137525-51-0 / 77591-33-4
The gold-standard recovery stack. BPC-157 (Body Protection Compound) accelerates healing of tendons, ligaments,
muscle, gut lining, and bone via nitric oxide modulation, angiogenesis, and growth factor upregulation. TB-500 (Thymosin
Beta-4) promotes actin polymerization, cell migration, and systemic tissue repair. Together they provide local (BPC) and
systemic (TB-500) healing coverage.
DOSING PROTOCOL
| Parameter | Details |
|---|---|
| Acute Injury Dose | 250–500 mcg BPC-157 + 2.5–5 mg TB-500 (SubQ or IM) |
| Frequency | Daily for 2 weeks, then every other day (EOD) |
| Maintenance Dose | 2–3× per week (SubQ) |
| Timing | Any time; BPC-157 may be administered near the injury site for localized effect |
| Cycle Length | 4–8 weeks (acute protocols); 8–12 weeks (maintenance protocols) |
STACKING RECOMMENDATIONS
Combine with GH secretagogues (GAINZ PRO, CJC+IPA) for enhanced connective tissue repair. HGH 191AA accelerates
tendon collagen synthesis. Kisspeptin-10 for hormonal optimization during recovery.
NOTE: Bpc158+tb500 is orally bioavailable for gut issues. TB-500 requires injection. No hormonal suppression. Safe to run year-round at
maintenance doses.
From Collection
RETATRUTIDE | RETA-X
XENE BIOLABS RESEARCH SERIES
FOR RESEARCH USE ONLY
Category: GLP-1/GIP/Glucagon Tri-Agonist | Half-life: 6 days
Mechanism
Triple incretin agonist. GLP-1 + GIP + glucagon receptor activation. Superior weight loss to Semaglutide/Tirzepatide. Phase 3 trials.
Dosing Protocol
Critical: Slow titration mandatory. Severe nausea/vomiting if escalated too fast. Not FDA-approved yet. Research only.
